Clarity Financial LLC Has $47.66 Million Position in AbbVie Inc. $ABBV

Clarity Financial LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 1.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 205,855 shares of the company’s stock after buying an additional 3,372 shares during the quarter. AbbVie comprises about 4.7% of Clarity Financial LLC’s holdings, making the stock its 2nd largest position. Clarity Financial LLC’s holdings in AbbVie were worth $47,664,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in AbbVie during the second quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC raised its position in shares of AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. raised its position in shares of AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after purchasing an additional 3,666,521 shares during the period. Vanguard Group Inc. lifted its stake in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in AbbVie in the 2nd quarter worth approximately $581,817,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $227.44 on Monday. The stock has a market cap of $401.98 billion, a price-to-earnings ratio of 172.30, a PEG ratio of 1.29 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The business has a 50-day simple moving average of $226.63 and a 200 day simple moving average of $211.31. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of analyst reports. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.